Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2024 Jul;91(1):119-122.
doi: 10.1016/j.jaad.2024.02.045. Epub 2024 Mar 9.

Low incidence of invasive fungal infections in a large observational cohort of patients initiating IL-17 or IL-23 inhibitor therapy, United States, 2016-2022

Nathan C Bahr  1 , Kaitlin Benedict  2 , Mitsuru Toda  2 , Jeremy A W Gold  3 , Shari R Lipner  4
Affiliations
Observational Study

Low incidence of invasive fungal infections in a large observational cohort of patients initiating IL-17 or IL-23 inhibitor therapy, United States, 2016-2022

Nathan C Bahr et al. J Am Acad Dermatol. 2024 Jul.
No abstract available

Keywords: Candida infection; Crohn's disease; blastomycosis; brodalumab; candidiasis; coccidioidomycosis; esophageal candidiasis; guselkumab; histoplasmosis; inflammatory bowel disease; interleukin-17 inhibitors; interleukin-23 inhibitors; invasive fungal infection; ixekizumab; psoriasis; risankizumab; secukinumab; tildrakizumab; ustekinumab.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest Dr Lipner has served as a consultant for Ortho-dermatologics, Eli Lilly, Moberg Pharmaceuticals, and BelleTorus Corporation. The other authors declare no potential conflicts.

References

    1. Lee MP, Wu KK, Lee EB & Wu JJ Risk for deep fungal infections during IL-17 and IL-23 inhibitor therapy for psoriasis. Cutis 106, 199–205 (2020). 10.12788/cutis.0088 - DOI - PubMed
    1. Sticherling M et al. Secukinumab in Pediatric Patients with Plaque Psoriasis: Pooled Safety Analysis from Two Phase 3 Randomized Clinical Trials. Am J Clin Dermatol 24, 821–835 (2023). 10.1007/s40257-023-00782-8 - DOI - PMC - PubMed
    1. Feng Y et al. Risk of Candida Infection and Serious Infections in Patients with Moderate-to-Severe Psoriasis Receiving Biologics: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Int J Clin Pract 2022, 2442603 (2022). 10.1155/2022/2442603 - DOI - PMC - PubMed
    1. Blauvelt A et al. Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials. Br J Dermatol 179, 615–622 (2018). 10.1111/bjd.16724 - DOI - PubMed
    1. Saunte DM, Mrowietz U, Puig L & Zachariae C Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. Br J Dermatol 177, 47–62 (2017). 10.1111/bjd.15015 - DOI - PubMed

Publication types